Publicaciones en colaboración con investigadores/as de Instituto de Salud Carlos III (22)

2024

  1. Gut Microbiota Signatures with Potential Clinical Usefulness in Colorectal and Non-Small Cell Lung Cancers

    Biomedicines, Vol. 12, Núm. 3

2023

  1. Functional Proteomics Characterization of the Role of SPRYD7 in Colorectal Cancer Progression and Metastasis

    Cells, Vol. 12, Núm. 21

  2. Gut microbiota profiles in feces and paired tumor and non-tumor tissues from Colorectal Cancer patients. Relationship to the Body Mass Index

    PLoS ONE, Vol. 18, Núm. 10 OCTOBER

  3. p53 and p63 Proteoforms Derived from Alternative Splicing Possess Differential Seroreactivity in Colorectal Cancer with Distinct Diagnostic Ability from the Canonical Proteins

    Cancers, Vol. 15, Núm. 7

2022

  1. Spatial Proteomic Analysis of Isogenic Metastatic Colorectal Cancer Cells Reveals Key Dysregulated Proteins Associated with Lymph Node, Liver, and Lung Metastasis

    Cells, Vol. 11, Núm. 3

2021

  1. Multiplexed Biosensing Diagnostic Platforms Detecting Autoantibodies to Tumor-Associated Antigens from Exosomes Released by CRC Cells and Tissue Samples Showed High Diagnostic Ability for Colorectal Cancer

    Engineering, Vol. 7, Núm. 10, pp. 1393-1412

2020

  1. COPD in the Intensive Care Unit

    Seminars in Respiratory and Critical Care Medicine

  2. Treatment patterns for metastatic colorectal cancer in Spain

    Clinical and Translational Oncology, Vol. 22, Núm. 9, pp. 1455-1462

2018

  1. Novel genetic mutations detected by multigene panel are associated with hereditary colorectal cancer predisposition

    PLoS ONE, Vol. 13, Núm. 9

2016

  1. Proteome-wide alterations on adipose tissue from obese patients as age-, diabetes- and gender-specific hallmarks

    Scientific Reports, Vol. 6

  2. Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable CT3-4 or N+ rectal cancer: Five-year disease-free survival results of a single-center series

    Clinical Colorectal Cancer, Vol. 15, Núm. 2, pp. 128-134

2015

  1. First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish cooperative group for the treatment of digestive tumours

    European Journal of Cancer, Vol. 51, Núm. 11, pp. 1371-1380

  2. Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02

    Cancer Chemotherapy and Pharmacology, Vol. 75, Núm. 2, pp. 319-324

2014

  1. TTD consensus document on the diagnosis and management of exocrine pancreatic cancer

    Clinical and Translational Oncology, Vol. 16, Núm. 10, pp. 865-878

2012

  1. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: A spanish cooperative group for the treatment of digestive tumors study

    Oncologist, Vol. 17, Núm. 7, pp. 947-955

  2. First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Onkologie, Vol. 6, Núm. 2, pp. 96-103

  3. First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: Clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD group study

    Oncologist, Vol. 17, Núm. 3, pp. 339-345

2011

  1. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD)

    Critical Reviews in Oncology/Hematology, Vol. 77, Núm. 1, pp. 78-84

  2. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer

    Breast Cancer Research and Treatment, Vol. 128, Núm. 1, pp. 127-136

2010

  1. Breast cancer: Complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma

    Anti-Cancer Drugs, Vol. 21, Núm. SUPPL.1